Ovensa and Celanese to collaborate to advance precision drug delivery

Tirzepatide has potential to drive weight loss market dramatically, observes GlobalData

Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022

USFDA approves novel, dual-targeted treatment for type 2 diabetes

In clinical trials, treatment proved more effective than other therapies evaluated

Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022

Cipla has reported consolidated financial results for the period ended March 31, 2022

Pfizer to acquire Biohaven Pharmaceuticals for US $ 11.6 billion

Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need

TB4 shows potential as a combination treatment for diabetes-induced complications of the cornea

The research was funded by the National Institutes of Health, the Eversight Center for Vision and Eye Banking Research, and Research to Prevent Blindness

Physicians foresee an Alzheimer's Disease treatment revolution supported by advanced testing tools

Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education

Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity

Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study

Novel Covid-19 vaccine may protect the immunocompromised

The peptide-based vaccine induces a t cell-dependent response

Enteris BioPharma gets featured on its oral drug delivery technology

Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability